As an alternative, recently developed methods for so-called liquid biopsy analyzing circulating tumor DNA (ctDNA) from peripheral blood can provide a rapid KRAS genotyping that is relatively non-invasive and with a minimal risk of complications compared to tissue biopsy [17,18]. The gene discussed is KRAS; the disease is neoplasm.